CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 48 enrolled
Drug / intervention
Desmopressin Acetate 0.2 mg Tablets +1 moredrug
Likely dose
Desmopressin Acetate 0.2 mg Tabletsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00835211
NCT00835211Phase 1Completed
CompareCT.gov

Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of TEVA and Aventis Pharmaceuticals (DDAVP®) 0.2 mg Desmopressin Acetate Tablets in Healthy Adult Subjects Following a 0.8 mg Dose Under Fasting Conditions

Teva Pharmaceuticals USA·interventional·Posted Feb 3, 2009·Updated Sep 11, 2009

In Brief

A Phase 1 clinical trial evaluating Desmopressin Acetate 0.2 mg Tablets and DDAVP® 0.2 mg Tablets for Healthy. Completed, enrolled 48 participants across 1 site.

Detailed Summary

The objective of this study was to compare the single-dose relative bioavailability of TEVA and Aventis Pharmaceuticals (DDAVP®) 0.2 mg desmopressin acetate tablets following a 0.8 mg dose under fasting conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesCanada
Collaborators--

Timeline

Phase 1CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 3, 2009
Enrollment StartJul 1, 2003
Primary CompletionAug 1, 2003
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 17.4 years ago

Interventions

Desmopressin Acetate 0.2 mg Tabletsdrug

4 x 0.2 mg, single-dose fasting

DDAVP® 0.2 mg Tabletsdrug

4 x 0.2 mg, single-dose fasting